期刊
EUROPACE
卷 23, 期 9, 页码 1502-1507出版社
OXFORD UNIV PRESS
DOI: 10.1093/europace/euab106
关键词
Atrial fibrillation; Low stroke risk; Cardioversion; Anticoagulation; Non-vitamin K antagonist oral; anticoagulants; Vitamin K antagonist; EHRA survey
The survey results showed heterogeneity in anticoagulation management before and after cardioversion in low stroke-risk patients with atrial fibrillation duration <48 hours. Periprocedural low-molecular-weight heparin was used more than non-vitamin K antagonist oral anticoagulants, and there was higher utilization of pre-cardioversion transesophageal echocardiography for electrical cardioversion than for pharmacological cardioversion.
Data supporting the safety of cardioversion (CV) of atrial fibrillation (AF) without anticoagulation in patients with AF duration <48 h are scarce. Observational studies suggest that the risk of stroke in these patients is very low when the definite duration of the AF episode is of <48 h and the clinical risk profile as estimated through the CHA2DS2VASc score is low (a score of 0 for men and 1 for women). As the recent 2020 European Society of Cardiology (ESC) guidelines indication for this clinical scenario is based mainly on consensus, we sent out a survey to assess the current clinical practice on anticoagulation prior to and post-CV in patients with AF <24-48 h duration and low stroke risk across centres in Europe. Of the 136 respondents, half were affiliated to university hospitals (68/136; 50%). Non-university hospitals (50/136; 36%) and private hospitals (2/136; 1.4%) accounted over a third of respondents. The main findings of our survey were (i) heterogeneity in the anticoagulation management both before and post-CV in low stroke-risk patients with AF <48 h, (ii) higher utilization of periprocedural lowmolecular-weight heparin than of non-vitamin K antagonist oral anticoagulant, (iii) higher utilization of pre-CV transoesophageal echocardiography for electrical CV than for pharmacological CV regardless of the duration of AF, (iv) high adherence to a 4-week post-CV oral anticoagulant (OAC) therapy, mainly for electrical CV, and finally, (v) perceived higher acceptance of lack of post-CV OAC therapy in patients with <24 h than 24-48 h episode duration. The results obtained in this survey highlight the need for more research providing definitive clarification on the safety of CV without anticoagulation in patients with short duration AF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据